WALTHAM, Mass., June 22 /PRNewswire/ -- AltaRex Corp. (AXO.TO, ALXFF.OTC)
announced today the appointment of Hans Wigzell, M.D., D.Sc. to its Scientific
Advisory Board (SAB). Dr. Wigzell holds the title of Professor at the
Department of Immunology of the Karolinska Institute in Stockholm, Sweden, as
well as President, a position he has held since 1995. Dr. Wigzell has a long
and distinguished career in immunology research for cancer and infectious
diseases, and specifically T cell receptor analysis. Dr. Wigzell has published
nearly 600 scientific articles in international journals. He is an honorary
member for life of the American Society for Immunology and is an elected
member of the Danish Academy of Sciences and Letters since 1986.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO )
"The addition of Dr. Wigzell to our Scientific Advisory Board is
representative of the level of excellence that we are able to engage, not only
from North America, but now from Europe as well. We believe that Dr.
Wigzell's appointment speaks to the level of sophistication of our novel
antigen-targeted antibody based immunotherapy, and to the potential of our
technology platform," commented Richard E. Bagley, President and CEO of
AltaRex.
"As we move towards our goal of filing for U.S. regulatory approval of the
Company's lead product OvaRex(R) MAb, and as we prepare to advance additional
programs, the voice of noted authorities in the field of immunology such as
Dr. Wigzell will support our efforts," added Antoine A. Noujaim, Ph.D.,
Chairman of the Scientific Advisory Board and Chief Scientific Officer of
AltaRex.
About AltaRex
AltaRex Corp. is focused on the research, development and
commercialization of antigen-targeted antibody-based cancer therapies,
utilizing monoclonal antibodies as immunotherapeutic agents for the treatment
of certain late-stage cancers.
The Company's lead product OvaRex(R) MAb targets the tumor associated
antigen CA 125 and is in final stages of clinical evaluation for the treatment
of advanced ovarian cancer. Clinical data reported from completed and ongoing
OvaRex(R) trials demonstrate patient benefit as measured by prolongation in
time to relapse and/or survival, without the toxicities seen with standard
chemotherapies. The compilation of OvaRex(R) data from six clinical studies
in over 500 ovarian cancer patients will form the basis for filing for
regulatory approval of OvaRex(R) MAb in the United States, a process
anticipated to begin in late 2001 or early 2002, assuming timely scale-up of
cell culture manufacturing. The Company's second antibody in development,
BrevaRex(R) MAb, targets the tumor associated antigen MUC1 and has completed a
phase I safety and immunology study, with a phase I/II study in multiple
myeloma patients scheduled to initiate during the third quarter of this year.
More about AltaRex research and development, clinical trials, news and
events can be found on its web site at http://www.altarex.com. AltaRex Corp. is
traded on the Toronto Stock Exchange under the symbol AXO, and over-the-
counter in the United States under the symbol ALXFF. Clinical trial
information can be found at http://www.centerwatch.com. Additional information about
ovarian cancer can be found at http://www.nci.nih.gov, http://www.ovarian.org.,
http://www.ovariancancer.org and at http://www.ovariancanada.org. Additional information
about multiple myeloma can be found at http://www.multiplemyeloma.org.
This news release contains forward-looking statements that involve risks
and uncertainties, which may cause actual results to differ materially from
the statements made. For this purpose, any statements that are contained
herein that are not statements of historical fact may be deemed to be forward-
looking statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "intends," "expects" and similar expressions are
intended to identify forward-looking statements. Such risks and uncertainties
include, but are not limited to our need for capital and the risk that the
Company can not raise funds on a timely basis on satisfactory terms or at all,
changing market conditions, completion of clinical trials, patient enrollment
rates, uncertainty of pre-clinical, retrospective and early clinical trial
results, which may not be indicative of results that will be obtained in
ongoing or future clinical trials, the establishment of manufacturing
processes and new corporate alliances, the timely development, regulatory
approval and market acceptance of the Company's products, uncertainty as to
whether patents will issue from pending patent applications and, if issued, as
to whether such patents will be sufficiently broad to protect the Company's
technology, and other risks detailed from time-to-time in the Company's
filings with the United States Securities and Exchange Commission and Canadian
securities authorities.
THE TORONTO STOCK EXCHANGE HAS NOT APPROVED OR DISAPPROVED OF THE
INFORMATION CONTAINED HEREIN.
SOURCE AltaRex Corp.
 back to top
Related links:
http://www.altarex.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/128163.html or fax,
800-758-5804, ext. 128163
CONTACT:
Sondra Henrichon, Director, Investor
Relations and Corporate Communications of AltaRex Corp.,
781-672-0138, ext. 1510, or shenrichon@altarex.com; or Wayne
Hendry, Investor Relations of The Equicom Group, Inc,
416-815-0700, ext. 238, or whendry@equicomgroup.com
|
